Idronoxil novel formulation - Kazia Therapeutics

Drug Profile

Idronoxil novel formulation - Kazia Therapeutics

Alternative Names: NOX-66

Latest Information Update: 16 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Noxopharm
  • Class Antineoplastics; Hormones; Isoflavones; Small molecules
  • Mechanism of Action Caspase stimulants; NADH oxidase inhibitors; Proto oncogene protein c-akt inhibitors; X-linked inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Prostate cancer

Most Recent Events

  • 06 Mar 2018 Efficacy and adverse events data from the phase Ib CEP-1 trial in Solid tumours presented at the European Society for Medical Oncology Congress - 2018 (ESMO-2018).
  • 22 Jan 2018 Kazia Therapeutics has intellectual property protection for idronoxil novel formulation
  • 27 Dec 2017 Kazia Therapeutics acquires idronoxil novel formulation from Noxopharm
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top